Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free
Summit Therapeutics NASDAQ SMMT
$3.86 0.0000 0.0000%
Today share price
UK
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 23 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

2.69B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
2.72B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.88
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
697.74M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
47.89 %
Upcoming events Summit Therapeutics All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Summit Therapeutics

Stock analysis Summit Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-1.65 13.17
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
34.67 3.74
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
5.79 9.25
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
0.07 0.06
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
-1,643.24 9.43

Price change Summit Therapeutics per year

3.22$ 10.99$
Min Max

Summary analysis Summit Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Summit Therapeutics

Revenue and net income Summit Therapeutics

All parameters
Stock news Summit Therapeutics All news
6 December 2022 в 16:31

Summit Therapeutics Shares Jump on Deal to License Lung-Cancer Drug

6 December 2022 в 16:31

Summit Therapeutics Shares Jump on Deal to License Lung-Cancer Drug

9 February 2022 в 16:30

Summit Therapeutics Postpones Planned Rights Offering >SMMT

9 February 2022 в 16:30

Summit Therapeutics Postpones Planned Rights Offering >SMMT

20 December 2021 в 16:50

Summit Therapeutics Shares Fall 24% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study

20 December 2021 в 16:50

Summit Therapeutics Shares Fall 24% After Failing to Meet Endpoint in Phase 3 Ri-CoDIFy Study

About company Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Address:
One Broadway, Cambridge, MA, United States, 02142
Company name: Summit Therapeutics
Issuer ticker: SMMT
ISIN: US86627T1088
Country: UK
Exchange: NASDAQ
Currency: $
IPO date: 2015-03-05
Sector: Healthcare
Industry: Biotechnology
Site: https://www.summittxinc.com

On which stock exchange are Summit Therapeutics (SMMT) stocks traded?

Summit Therapeutics (SMMT) stocks are traded on NASDAQ.

What is the ticker of Summit Therapeutics stocks (SMMT)?

The stock ticker of Summit Therapeutics’s stocks or in other words, the code is SMMT. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Summit Therapeutics (SMMT) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Summit Therapeutics (SMMT) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Summit Therapeutics (SMMT) stocks traded?

Summit Therapeutics (SMMT) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Summit Therapeutics (SMMT) stocks today?

The current price of Summit Therapeutics stocks on 29.04.2024 is 3.86 dollars. per share.

What is the dynamics of Summit Therapeutics (SMMT) stocks from the beginning of the year?

Summit Therapeutics (SMMT) quotes have increased by 46.21% from the beginning of the year up to 3.86 dollars. per 1 stocks.

How much did Summit Therapeutics (SMMT) stocks increase in апреле 2024?

This month Summit Therapeutics (SMMT) quotes have increased by -3.02% to 3.86 dollars. per share.

How much are Summit Therapeutics (SMMT) stocks worth?

Today, on October, 29.04.2024 Summit Therapeutics’s (SMMT) stocks cost 3.86 dollars..

What is the market capitalization of Summit Therapeutics (SMMT)?

Capitalization is the market value of Summit Therapeutics (SMMT) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 29.04.2024, the market capitalization of Summit Therapeutics (SMMT) is estimated at about 2693274381 dollars.